CYFIRMA Selected by Zuellig Pharma to Strengthen Cybersecurity Posture

With CYFIRMA's DeCYFIR platform, Zuellig Pharma has bolstered its cyber defense ammunition to accurately uncover cyberattacks at the early planning stage and take remedial actions to close vulnerabilities before hackers can compromise the network.

FREMONT, CA: CYFIRMA, a threat discovery and cyber-intelligence platform company funded by Goldman Sachs, Zodius Capital, and Z3Partners, announced that Zuellig Pharma, a leading healthcare services provider in Asia, has selected DeCYFIR, a cloud-based, AI-powered cybersecurity platform, to gain further visibility into its external threat landscape to uncover hacking campaigns and avert cyberattacks.

In the last 18 months, the COVID-19 pandemic has seen the global healthcare industry falling victim to cybercriminals taking advantage of the chaos. According to CYFIRMA researchers, cyberattacks on healthcare more than doubled in 2020. COVID-19 response efforts, including vaccine research and supply chain, were the largest focus of these targeted campaigns.

"As a healthcare services company delivering life-saving medicines to those who need them the most, we own and operate some of the most advanced cold chain facilities, managing temperature-sensitive medicines through innovative and digitalized processes. The rapidly evolving threat landscape in the healthcare industry has shown us the importance of managing cybersecurity in dynamic ways, particularly as we continue rolling out more digitalization initiatives. CYFIRMA's DeCYFIR will guide us in our response to cyber risks by providing us with real-time insights and early warnings to malicious activities targeting us," said Mike Brewster, Vice President Technology, Zuellig Pharma.

With CYFIRMA's DeCYFIR platform, Zuellig Pharma has bolstered its cyber defense ammunition to accurately uncover cyberattacks at the early planning stage and take remedial actions to close vulnerabilities before hackers can compromise the network. The platform enables further visibility into the external threat landscape by monitoring the dark web, hacker forums, and various closed communities to look for threat indicators that would signal cyber criminals planning to exploit security weaknesses that could lead to business disruption.

"We are honored to be working with Zuellig Pharma to deploy our DeCYFIR platform, which will play a pivotal role in helping them fend off cybercriminals who are out to pilfer intellectual property, conduct corporate espionage, cause business disruption, and damage brand and reputation. Cybercrime has escalated rapidly in recent times, and this is a clear sign that businesses need to relook at how they are currently managing their cybersecurity strategies and programs. DeCYFIR's ability to predict imminent attacks will give defenders the much-needed edge over cybercriminals," said Kumar Ritesh, Founder, and CEO, CYFIRMA. "